These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22855283)

  • 41. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
    Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.
    Diodati JG; Saucedo JF; French JK; Fung AY; Cardillo TE; Henneges C; Effron MB; Fisher HN; Angiolillo DJ
    Circ Cardiovasc Interv; 2013 Oct; 6(5):567-74. PubMed ID: 24065443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    Gurbel PA; Erlinge D; Ohman EM; Neely B; Neely M; Goodman SG; Huber K; Chan MY; Cornel JH; Brown E; Zhou C; Jakubowski JA; White HD; Fox KA; Prabhakaran D; Armstrong PW; Tantry US; Roe MT;
    JAMA; 2012 Nov; 308(17):1785-94. PubMed ID: 23117779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
    Angiolillo DJ; Badimon JJ; Saucedo JF; Frelinger AL; Michelson AD; Jakubowski JA; Zhu B; Ojeh CK; Baker BA; Effron MB
    Eur Heart J; 2011 Apr; 32(7):838-46. PubMed ID: 21252171
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.
    Ge J; Zhu J; Hong BK; Boonbaichaiyapruck S; Goh YS; Hou CJ; Pinton P
    Curr Med Res Opin; 2010 Sep; 26(9):2077-85. PubMed ID: 20629598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
    Erlinge D; Ten Berg J; Foley D; Angiolillo DJ; Wagner H; Brown PB; Zhou C; Luo J; Jakubowski JA; Moser B; Small DS; Bergmeijer T; James S; Winters KJ
    J Am Coll Cardiol; 2012 Nov; 60(20):2032-40. PubMed ID: 23083774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
    Schulz S; Richardt G; Laugwitz KL; Mehran R; Gershlick AH; Morath T; Mayer K; Neudecker J; Tölg R; Ibrahim T; Hauschke D; Braun D; Schunkert H; Kastrati A; Mehilli J;
    Clin Cardiol; 2014 May; 37(5):270-6. PubMed ID: 24633823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
    Dridi NP; Johansson PI; Clemmensen P; Stissing T; Radu MD; Qayyum A; Pedersen F; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2014; 25(7):506-12. PubMed ID: 24245960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.
    Ferreiro JL; Homs S; Berdejo J; Roura G; Gómez-Lara J; Romaguera R; Teruel L; Sánchez-Elvira G; Marcano AL; Gómez-Hospital JA; Angiolillo DJ; Cequier Á
    Thromb Haemost; 2013 Jul; 110(1):110-7. PubMed ID: 23615769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
    Cubero Gómez JM; Acosta Martínez J; Mendias Benítez C; Díaz De La Llera LS; Fernández-Quero M; Guisado Rasco A; Villa Gil-Ortega M; Sánchez González Á
    Acta Cardiol; 2015 Dec; 70(6):728-34. PubMed ID: 26717223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
    Valenti R; Marcucci R; Comito V; Marrani M; Cantini G; Migliorini A; Parodi G; Gensini GF; Abbate R; Antoniucci D
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1563-70. PubMed ID: 26386764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions: The PRAISE study.
    Guo LZ; Kim MH; Shin ES; Ann SH; De Jin C; Cho YR; Park JS; Park K; Park TH; Lee MS; Serebruany VL
    Int J Cardiol; 2016 Nov; 222():639-644. PubMed ID: 27517654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel.
    Mangiacapra F; Pellicano M; Di Serafino L; Bressi E; Peace AJ; Di Gioia G; Morisco C; Bartunek J; Wijns W; Bruyne B; Barbato E
    Atherosclerosis; 2018 Nov; 278():23-28. PubMed ID: 30236867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
    Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
    Fedor M; Samoš M; Šimonová R; Fedorová J; Škorňová I; Duraj L; Staško J; Kovář F; Mokáň M; Kubisz P
    Clin Appl Thromb Hemost; 2015 May; 21(4):334-8. PubMed ID: 24989714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.